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Head and neck squamous cell carcinoma (HNSCC) is
one of the most morbid, mortal, and genetically diverse
malignancies. Although HNSCC is heterogeneous in
nature, alterations in major components of the PI3K/
Akt/mTOR pathway are consistently observed through-
out the majority of HNSCC cases. These alterations
include genetic aberrations, such as mutations or DNA
copy number variations, and dysregulation of mRNA or
protein expression. In normal physiology, the PI3K/Akt/
mTOR axis regulates cell survival, growth, and metabo-
lism. However, alterations in this pathway lead to the
malignant phenotype which characterizes HNSCC,
among many other cancers. For this reason, both phar-
maceutical companies and academic institutions are
actively developing and investigating inhibitors of PI3K,
Akt, and mTOR in preclinical and clinical studies of
HNSCC. Many of these inhibitors have shown promise,
while the effects of others are tempered by the mecha-
nisms through which HNSCC can evade therapy. As
such, current research aimed at elucidating the interac-
tions between PI3K/Akt/mTOR and other important sig-
naling pathways which may drive resistance in HNSCC,
such as p53, NF-jB, and MAPK, has become a promi-
nent focus toward better understanding how to most
effectively treat HNSCC.
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Introduction
Head and neck cancer is the sixth most common cancer
worldwide and has a 5-year morbidity rate of ~50%
(Siegel et al, 2013). The histological diagnosis of head
and neck squamous cell carcinoma (HNSCC) accounts for
over 95% of all clinical cases of head and neck cancer
and is limited anatomically to one of five primary sites:
oral cavity, oropharynx, nasopharynx, hypopharynx, or
larynx (Leemans et al, 2011). In terms of genetic altera-
tions, HNSCC is one of the most heterogeneous of all
cancers (Vogelstein et al, 2013). However, The Cancer
Genome Atlas (TCGA; cancergenome.nih.gov) and other
studies recently revealed that the majority of HNSCC pos-
sess alterations in the PI3K/Akt/mTOR pathway (Grandis
et al, 2012; Hayes et al, 2013), a critical regulatory axis
for cell growth, survival, motility, and metabolism in both
normal physiology and cancer.
Phosphoinositide 3-kinase (PI3K), is composed of two
subunits – an 85-kDa regulatory subunit and a 110-kDa
catalytic subunit. It is activated in response to somatic
mutation, stimulated receptor tyrosine kinases (RTKs)
such as epidermal growth factor receptor (EGFR) and
insulin-like growth factor receptor 1 (IGF-1R), or G-pro-
tein-coupled receptors (GPCRs). PI3K catalytic subunit
alpha isoform (PIK3CA), the gene that programs for the
p110a isoform of PI3K, is one of the most frequently
mutated and amplified oncogenes in human cancers (Yuan
and Cantley, 2008), including HNSCC. In normal physiol-
ogy, PI3K is regulated by the tumor suppressor, Phospha-
tase and tensin homolog (PTEN). However, inactivating
mutation or loss of PTEN is a frequent alteration in cancer
and leads to hyperactivity of the PI3K pathway (Courtney
et al, 2010). Protein kinase B (Akt) and mammalian target
of rapamycin (mTOR) are effector proteins downstream of
PI3K and also play important roles in carcinogenesis.
Together, the members of the PI3K/Akt/mTOR axis inter-
act with and contribute to the regulation of several other
signaling molecules in HNSCC, including tumor suppres-
sor, tumor protein p53 [p53 (TP53)], nuclear factor-kappa
B (NF-jB), and mitogen-activated protein kinase
(MAPK)/extracellular signal-regulated kinase (ERK) (Fig-
ure 1). For these reasons, there has been a surge in the
development and use of pharmacologic inhibitors targeting
PI3K, Akt, and mTOR for cancers such as HNSCC
(Table 1). Initial preclinical and clinical studies indicate
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promise for PI3K and mTOR inhibitors to benefit patients
with HNSCC.
EGFR/PI3K/Akt/mTOR signaling in normal
physiology
The EGFR/PI3K/Akt/mTOR signaling cascade is critical
to cell growth, development, survival, and differentiation.
Epidermal growth factor receptor (EGFR), also known as
ErbB-1 or HER1, contains an extracellular ligand-binding
domain, a hydrophobic transmembrane portion, and a
cytoplasmic domain containing tyrosine kinase activity
and multiple phosphorylation sites (Kalyankrishna and
Grandis, 2006; Normanno et al, 2006; Freudlsperger et al,
2011). At least 30 ligands of the four ErbB family mem-
bers have been characterized (Rogers et al 2005). Ligand
binding triggers receptor activation through dimerization
and auto- or cross-phosphorylation of the tyrosine kinase
domains (Lu et al, 2012), which initiates EGFR signal
transduction through multiple intracellular pathways,
including the PI3K/Akt/mTOR pathway.
There are three classes of PI3Ks (I, II, and III), classified
by structure and substrate preference. Class I PI3Ks, the
subject of this review, are divided into subclasses IA and IB
(Vanhaesebroeck et al, 2012). While initially postulated
that IA enzymes are activated by RTKs, and IB enzymes are
stimulated through GPCRs, recent work shows crossover in
these stimuli (Katso et al, 2001). PI3K IA catalytic subunits
include p110a (PIK3CA), p110b, and p110d – all of which
contain an N-terminal p85 regulatory subunit-binding
domain and a Ras-binding domain (Domin and Waterfield,
1997; Fruman et al, 1998). p110a and p110b are ubiqui-
tously expressed, while p110d is mainly found in leuko-
cytes, as it is a key player in lymphoid differentiation and
development (Vanhaesebroeck et al, 2010). PI3K class IB
includes the catalytic p110c subunit, which is similar to the
p110a-d subunits, but does not contain a p85-binding site
(Katso et al, 2001). Activated EGFR recruits and activates
class IA PI3K at the membrane through direct binding of
the Src homology 2 domains of p85 with the phosphotyro-
sine residues of the activated receptor (Engelman, 2009).
Upon activation, the catalytic p110 subunit phosphorylates
phosphatidylinositol-4,5-bisphosphate (PIP2), converting it
into phosphatidylinositol-3,4,5-trisphosphate (PIP3). Tumor
suppressor PTEN antagonizes PI3K function by dephospho-
rylating PIP3 to regenerate PIP2. PIP3 functions as a second
messenger with binding sites for signaling proteins with
pleckstrin homology (PH) domains including 3-phospho-
inositide-dependent protein kinase-1 (PDK1) and Akt
(protein kinase B) (Liu et al, 2009).
Akt is a serine/threonine protein kinase with three iso-
forms (Akt1, Akt2, and Akt3) (Bellacosa et al, 1991),
which require phosphorylation for activation (Scheid and
Woodgett, 2001). Akt’s N-terminal region contains a PH
domain that interacts with PI3K products and initiates its
recruitment to the plasma membrane, conformational
change, and subsequent phosphorylation. Upon binding
with PIP3, Akt is phosphorylated at three different sites:
threonine 308 stabilizing the activation loop of the cata-
lytic kinase domain by Phosphoinositide dependent kinase
(PDK1) (Vivanco and Sawyers, 2002), serine 473 in the
hydrophobic COOH-terminal domain by mTORC2
(mTOR complex 2) (Sarbassov et al, 2005), and serine
129 between the PH and catalytic domains by casein
kinase 2 (CK2) (Di Maira et al, 2005). Activated Akt has
multiple downstream targets involved in cell survival,
growth, proliferation, angiogenesis, metabolism, and
migration (Manning and Cantley, 2007).
A major downstream effector of Akt is mTOR, also a
serine/threonine protein kinase, and the catalytic subunit
of mTOR complex 1 (mTORC1). mTORC1 regulates pro-
tein translation through phosphorylation of protein synthe-
Figure 1 Interactive signaling of PI3K/Akt/
mTOR and other pathways. Relationships
between well-characterized molecular signaling
routes in HNSCC (EGFR/PI3K/PTEN/Akt/
mTOR, RAS/RAF/MEK/ERK, IKK/NF-jB,
and MDM2/p53) are shown by black arrows
(activating interactions) and dashed red lines
(negative regulation). PI3K/Akt/mTOR
activation or inhibition ultimately regulates the
activity of many kinases and transcription
factors (purple) important in the nuclear control
of cell survival and the malignant phenotype
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sis components based on growth factor and nutrient avail-
ability (Hennessy et al, 2005). mTORC1 and mTORC2
are structurally and functionally unique complexes;
mTORC1 contains raptor (rapamycin-sensitive adaptor
protein of mTOR), while mTORC2 binds rictor (rapamy-
cin-insensitive companion protein of mTOR). Activation
of mTORC1 occurs through Akt-mediated inactivation of
the tuberous sclerosis complex (TSC). The TSC consists
of a heterodimer of tumor suppressor proteins hamartin
(TSC1) and tuberin (TSC2) and antagonizes mTOR sig-
naling by inhibiting the Ras-like small GTPase, Ras-
homolog enriched in brain (Rheb), a direct regulator of
mTOR signaling (Li et al, 2004; Pan et al, 2004). Well-
characterized targets of mTORC1 include ribosomal pro-
tein S6 kinase (RPS6K or S6K) and eukaryote initiation
factor 4E-binding protein 1 (EIF4EBP1 or 4EBP1), both
key regulators of protein translation. S6K phosphorylation
of the S6 protein increases translation of ribosomal pro-
teins and translation regulators (Meyuhas, 2000; Inoki
et al, 2005). 4EBP1, a translation inhibitor, binds and
inhibits eukaryotic translation initiation factor 4E (eIF-4E),
which initiates translation (Gingras et al, 1999). mTORC2
regulates actin cytoskeletal reorganization and serves as a
hydrophobic motif kinase for Akt at serine 473 (Bhaskar
and Hay, 2007).
EGFR/PI3K/Akt/mTOR pathway aberrations
in HNSCC
Recent developments in deep sequencing of tumor tissues
have paved a powerful path for discovery of the most fre-
quent genetic alterations in HNSCC. Unbiased high-
throughput approaches have revealed that PIK3CA is one
of the most commonly mutated and amplified genes in the
Table 1 Currently ongoing clinical trials of PI3K/Akt/mTOR inhibitors targeting HNSCC and solid tumors. All ongoing clinical trials of PI3K/Akt/
mTOR inhibitors that include any patients with HNSCC are listed, unless noted otherwise. The three most common adverse events associated with each
agent are presented in order of frequency reported, to date. Clinical trial IDs are indexed by http://clinicaltrials.gov (National Institutes of Health)
Drug (company) Combination Status Clinical trial ID Condition Adverse events
PI3K Inhibitors
BKM120
(Novartis, East
Hanover, NJ, USA)
Cetuximab Phase I/II NCT01816984 Recurrent or metastatic HNSCC Rash, hyperglycemia,
diarrheaSingle agent Phase II NCT01737450 Metastatic, recurrent, or progressive
HNSCC
PX-866
(Oncothyreon,
Seattle, WA, USA)
Cetuximab Phase I/II NCT01252628 Incurable, progressive, recurrent or
metastatic HNSCC
Diarrhea, nausea,
vomiting
Docetaxel Phase I/II NCT01204099 Locally advanced, recurrent or metastatic
HNSCC
BYL719
(Novartis)
Cetuximab Phase Ib/II NCT01602315 Recurrent or metastatic HNSCC Nausea, hyperglycemia,
diarrheaSingle agent Phase Ia NCT01219699 Advanced solid malignancies, including
HNSCC, with an alteration of PIK3CA
mTOR Inhibitors
Everolimus
(Novartis)
Single agent Phase II NCT01051791 HNSCC Rash, mucositis, fatigue
Single agent Phase II NCT01133678 HNSCC
Carboplatin,
cetuximab
Phase I/II NCT01283334 Advanced HNSCC
Carboplatin,
paclitaxel
Phase I/II NCT01333085 Unresectable or inoperable locally
advanced HNSCC
Cetuximab Phase I NCT01637194 Metastatic or recurrent HNSCC
Erlotinib Phase II NCT00942734 HNSCC
Rapamycin
(Pfizer, New York,
NY, USA )
Single agent Phase I/II NCT01195922 Previously untreated HNSCC Hyperglycemia, nausea,
anemia
Temsirolimus
(Pfizer)
Single agent Phase II NCT01172769 HNSCC Rash, mucositis, mood
disturbanceCetuximab Phase II NCT01256385 Recurrent or metastatic HNSCC
Carboplatin,
paclitaxel
Phase I/II NCT01016769 HNSCC
PI3K/mT0R Dual Inhibitors
BEZ235
(Novartis)
Everolimus Phase Ib NCT01508104 Metastatic or unresectable advanced
solid tumorsa
Fatigue, nausea, diarrhea
PF-04691502
(Pfizer)
Single agent Phase I NCT00927823 Advanced solid tumors including
HNSCC
Fatigue, nausea, vomiting
PF-05212384
(Pfizer)
Docetaxel, cisplatin,
dacomitinib
Phase I NCT01920061 Advanced solid tumorsa Mucositis, nausea, fatigue
PD-901, irinotecan Phase I NCT01347866 Advanced solid tumorsa
SAR245409
(Sanofi, Bridgewater,
NJ, USA)
Pimasertib Phase I NCT01390818 Advanced solid tumorsa Rash, diarrhea, fatigue
Akt Inhibitors
MK2206
(Merck, Whitehouse
Station, NJ, USA)
Single Agent Phase II NCT01349933 Recurrent or metastatic HNSCC Rash, nausea, pruritis
HNSCC, Head and neck squamous cell carcinoma.
aOpen to all solid tumors including non-small-cell lung carcinoma, but might not include Head and neck squamous cell carcinoma HNSCC.
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protein-coding human HNSCC genome (Agrawal et al,
2011; Stransky et al, 2011), which validates earlier
PIK3CA-targeted studies (Okami et al, 1998; Kozaki et al,
2006; Qiu et al, 2006; Murugan et al, 2008; Cohen et al,
2011; Morris et al, 2011). PIK3CA missense mutations
are concentrated in three ‘hotspots’ on chromosome 3q26
(H1047R, E545K, and E542K) known to affect constitu-
tive PI3K activity (Samuels et al, 2004). Recent mutation
analysis of 279 patients with HNSCC by TCGA has pro-
vided evidence that PIK3CA mutations are among the
most frequent mutations in HNSCC (18% in HPV-nega-
tive cancers and 37% in HPV-positive cancers) (Grandis
et al, 2012; Hayes et al, 2013). Altogether, genetic
changes (mutation or DNA copy number variation) in
major components of the PI3K pathway are represented in
66% of the TCGA HNSCC cases studied (Figure 2).
When including changes in mRNA expression, this
statistic jumps to over 90% (http://www.cbioportal.org),
with alterations in one component of the pathway often
being mutually exclusive with changes in a different com-
ponent. PIK3CA DNA copy number is amplified in 20%
of TCGA cases and mRNA expression is upregulated in
52% the TCGA tumors (Iglesias-Bartolome et al, 2013),
with reduced PTEN expression in ~30% of another
HNSCC cohort (Squarize et al, 2013). As a whole, the
cumulative changes in PI3K/Akt/mTOR and molecules
that communicate with this axis are represented at a sig-
nificant rate in HNSCC. Consequently, it serves as an
attractive target for molecular-oriented therapy.
A recent analysis showed that druggable events (copy
gain with increased expression or activating mutation)
associated with the PIK3CA or AKT1/2/3 loci could be
targeted in 12/35 (34%) HNSCC tumors sequenced
(Pickering et al, 2013). In a functional test of the drugga-
bility of PIK3CA mutations in HNSCC patient tumor
grafts, mutated rather than wild-type PIK3CA conferred a
greater sensitivity to the PI3K/mTOR inhibitor BEZ-235
(Lui et al, 2013). The same result held true for the PI3K
inhibitor PX-866 in HNSCC patient tumor grafts (Keysar
et al, 2013). Thus, the predilection of PI3K inhibitors
activity for HNSCC with PIK3CA activating mutations
provides one rationale for using PIK3CA mutational status
as a predictor of treatment selection. When considering
the importance of human papilloma virus (HPV) oncopro-
teins E6 and E7 in the etiology of a subset of HNSCC,
and the association of HPV with PI3K pathway mutations,
this rationale is strengthened. In a directed analysis of 15
genes in 64 HNSCC tumors, PIK3CA mutation was the
most abundant mutation, found at a much higher fre-
quency in the oropharynx than in any other primary site
(McBride et al, 2013). This observation is consistent with
a putative association between higher rates of HPV infec-
tion in oropharynx than in other head and neck cancer
anatomic sites (Gillison et al, 2000), and higher rates of
PIK3CA mutation in HPV+ HNSCC than in HPV-
HNSCC (Lui et al, 2013; Nichols et al, 2013).
PI3K/Akt/mTOR aberrations promote the
malignant phenotype
Functionally, aberrations in the PI3K/Akt/mTOR pathway
are associated with many of the malignant characteristics
of HNSCC, including immune suppression and inflamma-
tion, angiogenesis, survival, invasion, and metastasis.
Inflammation, in specific, regulates many of these pro-
cesses simultaneously (Grivennikov et al, 2010). In
contrast to ubiquitously expressed PI3K p110-a and
-b isoforms, p110-d is mainly present in leukocytes and
Figure 2 The frequency of genetic alterations of signaling molecules involved in PI3K pathway. The genetic data were obtained from cBioPortal for
Cancer Genomics (http://www.cbioportal.org), where the data from The Cancer Genome Atlas (TCGA) project were deposited. The data were collected
from 279 HNSCC tumor samples through high-throughput sequencing and other array technologies. Samples with genomic amplification (red), homozy-
gous deletion (blue), and/or mutation (green) are presented in the OncoPrint as individual bars or square dots. Only those samples with genetic altera-
tions in the PI3K/Akt/mTOR pathway are presented (183/279 tumors = 66% of cases). Percentages reflect the frequency with which samples express
any of the three alterations reported in a given gene. Copy number variations are putative. PI3K catalytic subunit alpha isoform (PIK3CA); epidermal
growth factor receptor (EGFR); eIF-4E binding protein 1 (EIF4EBP1); ribosomal protein S6 kinase (RPS6KB); Harvey rat sacrcoma virus oncogene
(HRAS); protein kinase B (AKT); 3-phosphoinositide dependent protein kinase 1 (PDK1); phosphatase and tensin homolog (PTEN); tuberous sclerosis
(TSC); Ras-homolog enriched in brain (RHEB); mammalian target of rapamycin (mTOR)
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p110-c in myeloid cells (Koyasu, 2003; Vanhaesebroeck
et al, 2005). As such, both p110-d and p110-c are crucial
for promoting inflammation in the cancer microenviron-
ment. Although most of the PI3K pathway-directed
anti-cancer therapies have aimed at p110-a suppression,
isoform-specific inhibition of p110- d or -c also attenuates
dysregulated inflammatory and immunosuppressive
responses and may have an improved safety profile
(Rommel et al, 2007; Fruman and Rommel, 2011; Schmid
et al, 2011).
Dysregulated inflammatory signaling mediates angio-
genesis, a critical process enabling tumor growth and
spread. Angiogenesis is promoted by the secretion of cyto-
kines such as vascular endothelial growth factor (VEGF),
basic fibroblast growth factor (b-FGF), and interleukin-8
(IL-8) by tumor cells and associated myeloid lineage infil-
trating cells. PI3K is activated downstream of the recep-
tors for these signaling molecules and acts as a master
regulator of angiogenesis and associated cytokine release
(Yuan and Cantley, 2008). mTORC1 phosphorylation of
eIF-4E facilitates tumor progression by increasing b-FGF
and VEGF and increases risk for second primary in histo-
logically cancer-free surgical margins (Nathan et al,
1999). While increased VEGF is associated with poor
prognosis in HNSCC (Luangdilok et al, 2011), we have
shown that pharmacologic inhibition of PI3K reduces
phosphorylation of Akt in HNSCC cell lines, thereby
blocking the secretion of VEGF and IL-8, even under epi-
dermal growth factor (Bancroft et al, 2002) or hepatocyte
growth factor stimulation (Dong et al, 2001a). In preclini-
cal mouse studies, constitutive Akt activity causes abnor-
mal vascular patterning (Hamada et al, 2005), and
conditional class IA PI3K knockout compromises vascular
integrity, limiting tumor size (Graupera et al, 2008; Yuan
et al, 2008).
Although the PI3K/Akt/mTOR pathway enables vascu-
lar formation and growth factor delivery to tumors, it also
confers a selective growth advantage and survival in con-
ditions of nutrient deprivation. Normal cells live within
100–200 lm of a capillary bed, the diffusion limit of oxy-
gen (Baish et al, 2011). Malignant cells with aberrations
in PIK3CA, PTEN, or MTOR, however, are able to con-
tinue proliferating in hypoxic conditions outside of this
range because of a modified cellular response to hypoxic
stress, nutrient sensing, insulin signaling, and glucose
uptake (Abraham, 2004; Kalaany and Sabatini, 2009;
Kang et al, 2013; Vogelstein et al, 2013). Akt also pro-
motes cell survival by attenuating pro-apoptotic factors,
BAD, BAX, procaspase-9, and FOXO (Hennessy et al,
2005; Engelman et al, 2006).
Tumor outgrowths as a result of aberrant PI3K/Akt/mTOR
signaling can subsequently lead to invasion (Samuels et al,
2005). Mechanistically, PI3K oncogenic disruption through
PTEN loss disturbs membrane polarity and leads to epithe-
lial-to-mesenchymal transition (Martin-Belmonte and
Mostov, 2008), a key event causing invasion. 3q26 (PIK3CA
locus) copy number gain and amplification is much more fre-
quent in invasive carcinoma and high-grade dysplasia than in
low-grade dysplasia (Woenckhaus et al, 2002). Late-stage
HNSCC lesions also express higher levels of PI3K p110a
mRNA and protein (Woenckhaus et al, 2002), lower levels
of PTEN (Squarize et al, 2002, 2013), and more simulta-
neous mutations in multiple PI3K pathway genes (Lui et al,
2013). In addition, increased phospho-Akt and phospho-S6
expressions have been correlated with HNSCC progression
(Amornphimoltham et al, 2004; Molinolo et al, 2007). This
suggests that disruption of any number of components in the
PI3K pathway might act as an oncogenic switch leading to
invasion. Once invasion has occurred, PI3K-PTEN interplay
regulates chemotaxis and intravasation of cells into endothe-
lial networks (Kolsch et al, 2008). Consequently, the capac-
ity of the PI3K/Akt/mTOR pathway to concurrently regulate
the processes of angiogenesis, cell motility, and invasion also
gives it solid footing for contributions to metastasis.
Accordingly, lymph node metastases are directly associ-
ated with PIK3CA gain and mutation (Fenic et al, 2007).
Because metastasis is the leading cause of death for patients
with solid tumors, PI3K activation portends a worse prog-
nosis. Indeed, two independent studies of HNSCC show
that 3q26 gain (PIK3CA locus) can predict poor clinical
outcome for patients with early disease tumors that have
not yet metastasized (Redon et al, 2001; Suda et al, 2012).
Reduced PTEN expression is a separate prognostic indica-
tor of poor clinical outcome (Lee et al, 2001). Additionally,
mTOR blockade is able to diminish lymphangiogenesis and
cervical lymph node spread, thereby increasing survival
(Patel et al, 2011). Because PI3K, Akt, and mTOR activa-
tion and PTEN inactivation are all independently associated
with adverse outcome in HNSCC (Nathan et al, 2004;
Massarelli et al, 2005; Molinolo et al, 2009), they serve as
logical targets in clinical trials.
PI3K/Akt/mTOR interactions with other
signaling molecules
TP53 is one of the best-studied and most frequently
deleted or mutated tumor suppressor genes. Inactivation of
p53 can occur through physical association with murine
double minute 2 homolog (MDM2), which results in cen-
trosome hyperamplification, chromosomal instability, and
aberrant mitosis (Carroll et al, 1999). PI3K phosphoryla-
tion of Akt activates MDM2 by translocating it from the
cytoplasm to the nucleus, thereby diminishing cellular lev-
els of p53 (Mayo and Donner, 2001). Concurrent inacti-
vating mutations in TP53 and activating abnormalities in
PIK3CA are uncommon in cancer, implying that they are
often mutually exclusive and independent promoters of
malignancy. In HNSCC, PI3KCA activation confers resis-
tance to p53-induced apoptosis, while p53-mediated apop-
tosis involves transcriptional inhibition of PIK3CA (Singh
et al, 2002). We have shown that treatment with the
PI3K/mTOR inhibitor, PF-04691502 (PF-502), induces
apoptosis and expression of wild-type p53 in two separate
in vivo models of HNSCC (Herzog et al, 2013). We have
also provided evidence that Akt inhibition reverses the
direct suppression of p53 by transcriptional and post-trans-
lational mechanisms (Friedman et al, 2013). In glioma
and endothelial cells, PI3K inhibition has also been
reported to increase p53 transactivation and transcription
of its target genes (Su et al, 2003). Furthermore, p53 is
able to induce PTEN, favoring cell death in malignancy
(Mayo and Donner, 2002). Other studies have evinced that
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mTOR signaling contributes to p53 inactivation through
IGF-1R-mediated upregulation of MDM2 (Du et al,
2013), and the use of the mTOR inhibitor, rapamycin, is
able to prevent oral cancer progression in a K-ras/p53
double-knockout mouse model (Raimondi et al, 2009).
Thus, therapies targeting PI3K/mTOR may be doubly
effective because of their capacity to both limit PI3K/Akt/
mTOR-mediated growth and survival and intensify p53-
mediated apoptosis.
In contrast to loss of p53 as a mechanism for evading
apoptosis, overactivity of the transcription factor, NF-jB,
is another important anti-apoptotic and prosurvival event
in HNSCC (Van Waes, 2007). We have compiled a large
body of evidence showing that NF-jB regulates the gene
expression and secretion of multiple cytokines and chemo-
kines that favor tumor progression (Chen et al, 1998,
1999; Duffey et al, 1999; Loukinova et al, 2000; Dong
et al, 2001b; Allen et al, 2007). Activation and nuclear
translocation of NF-jB occurs primarily through
phosphorylation of inhibitor-jB kinases (IKK) (Van Waes
et al, 2007; Nottingham et al, 2013), which can be phos-
phorylated downstream of active PI3K/Akt (Ozes et al,
1999; Romashkova and Makarov, 1999; Yang et al, 2001;
Hutti et al, 2012) in a cell-type-specific manner (Gustin
et al, 2004). Accordingly, we have shown that the PI3K
inhibitor, LY-294002, is able to reduce both constitutive
and inducible NF-jB activity in HNSCC (Bancroft et al,
2002). Furthermore, rapamycin has also been shown to
inhibit IKK activity, as the stimulation of IKK through
Akt requires the interaction of the mTOR-associated pro-
tein, raptor, with IKK (Dan et al, 2008). While the mecha-
nisms of interaction between the PI3K/Akt/mTOR and
NF-jB pathways have been elucidated in many cancers, it
remains to be studied further in HNSCC.
The PI3K/Akt/mTOR signaling route is also activated
in concert with the Ras/Raf (MAPK kinase kinase)/
MAPK pathway downstream of EGFR. Although the
contributions of these signaling pathways to malignancy
are often independent of EGFR overactivity, recent evi-
dence indicates that MAPK activity is differentially
affected by the EGFR-dependent PI3K/Akt/mTOR axis.
Many studies have shown that through various feedback
loops or resistance mechanisms, inhibition of one path-
way downstream of EGFR or IGF-1R causes compensa-
tory signaling through other parallel pathways (Carracedo
et al, 2008; Pernas et al, 2009; Ercan et al, 2012;
Limesand et al, 2013). The pleiotropy and resistance to
therapy of downstream EGFR signaling has led to pre-
clinical and clinical trials of combinations of EGFR,
PI3K, mTOR, MAPK kinase kinase, effector of Ras
(RAF), and MAPK kinase (MEK)/ERK inhibitors.
Although the interactions between the PI3K/Akt/mTOR
axis and p53, NF-jB, and MAPK signaling pathways are
perhaps the most studied, this is by no means an exhaus-
tive list of its interactions. The EGFR/PI3K/Akt/mTOR
axis has also been shown to be modified in HNSCC in
response to the modulation of transforming growth factor
beta (TGF-b) (Bian et al, 2012), signal transducer and
activator of transcription 3 (STAT3) (Lee et al, 2008;
Sen et al, 2012), and Wnt signaling (Kavitha et al,
2013), among others.
PI3K/Akt/mTOR inhibitors in clinical studies
The summary of currently ongoing clinical trials using
PI3K pathway inhibitors for head and neck cancer is pre-
sented in Table 1. BKM120, a pan-isoform PI3K inhibitor
which is furthest along in development, is currently in a
phase III trial for breast cancer (NCT01633060). Several
studies have been initiated to select for patients with
HNSCC, including a phase II trial using BKM120 as a
single agent and a phase I/II study combining BKM120
with cetuximab. The orally available, irreversible pan-iso-
form PI3K inhibitor PX-866 has also moved into phase II
trials for HNSCC. Although showing limited effect as a
single agent in solid tumors including HNSCC (Hong
et al, 2012), phase I/II trials combining PX-866 with ce-
tuximab and docetaxel have been initiated in patients with
HNSCC and may provide further insight into the efficacy
of this drug.
Several isoform-specific PI3K inhibitors are currently in
clinical trials, offering the potential benefit of improved
target selectivity with fewer off-target side effects. Of
these, only BYL719, a PI3Ka-specific inhibitor, has been
applied to patients with HNSCC. The phase I trial on this
drug was the first to selectively enroll patients with
advanced solid tumors with prescreened mutations or
amplifications of PIK3CA. In the dose escalation portion,
eight patients including those with oral cancers showed
prolonged disease stabilization lasting ≥4 months (Juric
et al, 2012), while the dose expansion study that followed
reported a partial response in 7/39 patients, one of which
had HNSCC (Gonzalez-Angulo, 2013). The safety profile
for BYL719 was similar to pan-PI3K inhibitors studied,
with the most common adverse effects including hypergly-
cemia, nausea, and GI toxicities. Based on the encourag-
ing results from this initial trial, BYL719 is currently
being evaluated in combination with cetuximab in a phase
Ib/II trial in patients with HNSCC.
Previously, the Akt inhibitor perifosine showed promis-
ing results in preclinical studies, but when moved to phase
II clinical trials in HNSCC, it failed to show any anti-
tumor effect (Argiris et al, 2006; Hideshima et al, 2006).
More recently, a newer Akt inhibitor MK-2206 has shown
synergistic activity with paclitaxel in preclinical models
and phase I trials of HNSCC (Ahmed et al, 2013). It is
currently being evaluated in phase II trials as a single
agent in recurrent or metastatic HNSCC and may prove to
be more effective than previous agents.
Rapamycin, the first mTOR inhibitor, targets mTOR
exclusively and has shown anti-tumor activity in preclini-
cal models (Amornphimoltham et al, 2005). The first clin-
ical trial of rapamycin as a single agent in HNSCC is
ongoing in phase I/II. Several rapamycin analogues have
been developed, including temsirolimus (CCI-779) and
everolimus (RAD001). Temsirolimus, after showing initial
safety and strong inhibition of mTOR targets S6 and 4E-
BP1 in HNSCC patient tumors (Ekshyyan et al, 2010),
has moved to phase II trials in HNSCC as a single agent,
in combination with carboplatin and paclitaxel or with
cetuximab. Meanwhile, everolimus is also being evaluated
extensively in HNSCC, with two phase I trials that have
recently completed. In the first trial, combining everolimus
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with cisplatin and docetaxel as induction therapy for radia-
tion, 2-year overall survival rate was 91% and progres-
sion-free survival rate at 2 years was 76.6% (Fury et al,
2013b). In the second trial, everolimus was given with
cisplatin and concurrent radiation, showing a 2-year
overall survival rate of 92% and 2-year progression-free
survival rate of 85% (Fury et al, 2013a). The most
impressive response, however, has come from the ongoing
phase I-II trials of everolimus in combination with car-
boplatin and paclitaxel as induction therapy in patients
with unresectable locally advanced HNSCC. Recently pre-
sented results showed a 2.6% complete response, 76.3%
partial response, as well as 21% stable disease in the 38
evaluable patients (Raymond et al, 2013). Everolimus
continues to be investigated alone and in combinations in
patients with HNSCC in five additional phase I-II trials
(Table 1).
An important drawback in selectively inhibiting mTOR
is the negative feedback loop that exists, in which S6K
phosphorylates and blocks insulin receptor substrate 1
(IRS1), leading to the activation of PI3K and subsequent
tumor growth (O’Reilly et al, 2006; Huang and Manning,
2009). To overcome this drawback, there is growing inter-
est in the development of dual PI3K-mTOR inhibitors that
can target the pathway at two points simultaneously. Dual
PI3K-mTOR inhibitors that have shown promising results
in preclinical studies of HNSCC include the orally avail-
able PF-502 (Herzog et al, 2013) and intravenously
administered PF-05212384 (PF-384). Preliminary results
from a phase I trial of PF-502, which is currently open to
HNSCC, but to date only includes other advanced solid
tumors such as non-small-cell lung carcinoma (NSCLC)
and colorectal carcinoma, have shown no objective tumor
reduction, but stable disease ≥16 weeks in approximately
16% of patients (LoRusso et al, 2011). Similarly, approxi-
mately 25% of patients with solid tumors including
NSCLC given weekly PF-384 as a single agent achieved
stable disease ≥16 weeks, although no objective tumor
reduction was observed (Tabernero et al, 2011). Addi-
tional phase I trials of PF-384 in combination with docet-
axel, cisplatin, and dacomitinib (EGFR inhibitor), as well
as irinotecan (topoisomerase 1 inhibitor) and PD-901
(MEK inhibitor), may prove to have greater anti-tumor
effects than single agents alone in HNSCC.
Conclusion and future directions
Following these initial clinical trials of agents targeting
the PI3K pathway, several key questions remain. Addi-
tional studies will necessitate decision making about the
most biologically active dose for each drug, the ideal
method of administration, and the acceptance of adverse
events including on-target effects such as hyperglycemia.
It remains to be determined which class of agents target-
ing PI3K, mTOR, or Akt will be most effective in
HNSCC, and whether there are factors that would make
one class superior to the other in specific cases. Several
clinical trials have retroactively analyzed PIK3CA muta-
tion status in patient samples, while few have limited
enrollment to patients with known PI3K pathway muta-
tions. There has been some evidence that preselected
patients with mutations in PI3K have better response to
treatment, revealing improved outcomes compared to non-
selective trials. Prescreening for molecular alterations has
proven beneficial in preclinical studies as well, as it has
uncovered critical mechanistic information regarding sensi-
tivity or resistance and effects on other pathways. PI3K
pathway cross-talk with other signaling routes, such as
p53, NF-jB, and MAPK, should be investigated more
extensively when designing future clinical trials. As large-
scale screening protocols for molecular alterations become
more prevalent in drug development trials, the feasibility
of translating genetic information about the PI3K/Akt/
mTOR axis to the clinic increases. Ultimately, this will
allow clinicians to tailor treatment to an individual molec-
ular profile and improve patient care.
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